- Conditions
- Alzheimer's Disease
- Interventions
- CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery
- Drug · Procedure
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Irregular Sleep-Wake Rhythm Disorder
- Interventions
- Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more
- Conditions
- Alzheimer's Disease
- Interventions
- Resveratrol, Placebo
- Drug
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- AAB-003 (PF-05236812)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 15
- States / cities
- Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
- Conditions
- Mild-To-Moderate Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Plasma
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Alzheimer's Disease
- Interventions
- Rosiglitazone XR
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 51 Years to 91 Years
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Deerfield Beach, Florida • Hialeah, Florida + 6 more
- Conditions
- Alzheimer's Disease
- Interventions
- AGN-242071, Placebo, Donepezil, Memantine
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 6
- States / cities
- Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more
- Conditions
- Alzheimer Disease
- Interventions
- xaliproden (SR57746A)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
- Conditions
- Alzheimer Disease
- Interventions
- MW150, Placebo
- Drug
- Lead sponsor
- Neurokine Therapeutics
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 41
- States / cities
- Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
- Conditions
- Alzheimer's Disease
- Interventions
- PPI-1019 (APAN)
- Drug
- Lead sponsor
- PRAECIS Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Orange, California • Princeton, New Jersey
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- AR1001 10mg, Placebo, AR1001 30mg
- Drug
- Lead sponsor
- AriBio Co., Ltd.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 21
- States / cities
- Banning, California • Sacramento, California • Santa Ana, California + 18 more
- Conditions
- Alzheimer's Disease
- Interventions
- SGS742
- Drug
- Lead sponsor
- Saegis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 88 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Alzheimer Disease
- Interventions
- caprylidene, Placebo
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Disease
- Interventions
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Alzheimer Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- rosiglitazone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 6
- States / cities
- Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
- Conditions
- Alzheimer's Disease
- Interventions
- PF-04447943, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Glendale, California • Gainesville, Florida • Hallandale, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- Curcumin C3 Complex
- Dietary Supplement
- Lead sponsor
- John Douglas French Foundation
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Westwood, Los Angeles, California
- Conditions
- Alzheimer's Disease
- Interventions
- CERE-110: Adeno-Associated Virus Delivery of NGF
- Genetic
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- San Diego, California • Chicago, Illinois